微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
RSS 官方收录 · 可信分层展示
关键摘要
诺和诺德终止ziltivekimab两项心血管炎症试验
- 因数据监委会判定难达终点，终止HERMES和ATHENA试验
- 此前ZEUS试验已失败：降炎但未降低心梗死亡风险
- ziltivekimab为靶向炎症改善心血管健康的在研药物
AI 摘要 · 来源可核验
正文提要
Novo Nordisk has stopped two trials of a drug that aims to tame inflammation as a way to improve cardiovascular health, another blow for the approach.
The company said it had halted the HERMES and ATHENA trials of its drug, ziltivekimab, after a data monitoring committee found they were unlikely to succeed. Novo informed trial investigators on Friday.
The move follows the earlier failure of the drug in the ZEUS trial, which showed that the medicine, despite lowering markers of inflammation, did not reduce the risk of major clinical complications, including deaths and heart attacks.